Originalarbeiten mit Erst-/Letztautorenschaft

  1. Westphal S, Beyer K, Kielstein V, Schenk H. Abnormal gangliosides in the plasma of alcoholics. Drug Alcohol Depend 1989;24:251-3. Impact-Faktor: 2,7
  2. Westphal S, Haselhorst U, Kielstein V, Schenk H. Veränderte Zusammensetzung für Ganglioside in den Membranen der Erythrozyten und im Plasma alkoholabhängiger Kranker. Z. med. Lab. diagn. 1990;31:371-374.
  3. Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomi-crons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr 2000;71:914-20. Impact-Faktor: 5,7
  4. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001;358:39-40. Impact-Faktor: 18
  5. Westphal S, Gekeler GH, Dierkes J, Wieland H, Luley C. A free fatty acid tolerance test identifies patients with coronary artery disease among individuals with a low conventional risk profile. Heart Vessels 2002;16:79-85. Impact-Faktor: 0,6
  6. Westphal S, Leodolter A, Kahl S, Dierkes J, Malfertheiner P, Luley C. Addition of glucose to a fatty meal delays chylomicrons and suppresses VLDL in healthy subjects. Eur J Clin Invest 2002;32:322-7. Impact-Faktor: 2,0
  7. Westphal S, Rading A, Luley C, Dierkes J. Antihypertensive Treatment and Homo-cysteine Concentrations. Metabolism 2003;52:261-3. Impact-Faktor: 2,0
  8. Westphal S, Wiens L, Güttler K, Dierkes J, Luley C. Chylomicron remnants of vari-ous sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis 2003;171:369-77. Impact-Faktor: 3,6
  9. Westphal S, Kastner S, Taneva E, Leodolter A, Dierkes J, Luley C. Postprandial lipid and carbohydrate responses after the ingestion of a casein-enriched mixed meal. Am J Clin Nutr 2004;80:284-90. Impact-Faktor: 5,7
  10. Westphal S, Borucki K, Luley C, Martens-Lobenhoffer J, Bode-Böger SM. Treat-ment with niacin lowers ADMA. Atherosclerosis 2006;184:448-50. Impact-Faktor: 3,6
  11. Taneva E, Wiens L, Makarova R, Borucki,K, Schmidt-Lucke C, Luley C, Westphal S. Atorvastatin Treatment and Withdrawal: Early Effects on Endothelial Function. Am J Cardiol. 2006;97:1002-6. Impact-Faktor: 3,1
  12. Westphal S, Taneva E, Kästner S, Martens-Lobenhoffer J, Bode-Böger S, Dierkes J, Luley C. Endothelial dysfunction induced by postprandial lipemia is neutralized by addition of proteins to the fatty meal. Atherosclerosis. 2006;185:313-9. Impact-Faktor: 3,6
  13. Westphal S, Katrin Borucki, Elena Taneva, Ruma Makarova, Claus Luley. Adi-pokines and Treatment with Niacin. Metabolism. 2006;55:1283-5. Impact-Faktor: 2,5
  14. Westphal S, Katrin Borucki, Elena Taneva, Ruma Makarova, Claus Luley. Exended-Release Niacin raises Adiponectin and Leptin. Atherosclerosis. 2007;193:361-365. Impact-Faktor: 4,3
  15. Wiens L, Lutze G, Luley C, Westphal S. Platelet count and platelet activation: Im-pact of a fat meal and day time. Platelets. 2007;18:171-3. Impact-Faktor: 2,0
  16. Westphal S, Luley C. Preferential increase in high-molecular weight adiponectin af-ter niacin. Atherosclerosis. 2008;198:179-83. Impact-Faktor: 4,6
  17. Westphal S, Abletshauser C, Luley C. Fluvastatin Treatment and Withdrawal: Ef-fects on Endothelial Function. Angiology. 2008;59:613-8. Impact-Faktor: 1,1
  18. Westphal S, Abletshauser C, Borucki K, Klima H, Luley C. The lowering of small dense LDL in patients with the metabolic syndrome by simvastatin/ezetimibe versus Fluvastatin/fenofibrate. Abstracts of the AACC Annual Meeting. July 27-31, 2008. Washington, DC, USA. Clin Chem. 2008;54(6 Suppl):A151. Impact-Faktor: 3,8
  19. Borucki K, Aronica S, Starke I, Luley C, Westphal S. 2.5 g L-arginine in a fat load abolishes the lipemia-induced endothelial dysfunction in healthy volunteers. Athero-sclerosis. 2009;205:251-4. Impact-Faktor: 4,3
  20. Westphal S, Abletshauser C, Luley C. Different Galenic Formulations of Fluvastatin Have Equal Lipid-Lowering Action but Differ in Reducing Lipemia-Induced Endothelial Dysfunction. Coron Artery Dis. 2009;20:81-5. Impact-Faktor: 0,9
  21. Steiner J, Walter M, Schiltz K, Myint A M, Bielau H , Brisch R, Keilhoff G, Bern-stein H-G, Bogerts B, Westphal S. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology. 2010;35:321-4. Impact-Faktor: 4,4
  22. Reiche I, Westphal S. Martens-Lobenhoffer J, Tröger U, Luley C, Bode-Böger SM. Pharmacokinetics and dose recommendations of Niaspan(R) in chronic kidney dise-ase and dialysis patients. Nephrol Dial Transplant. 2011;26:276-82. Impact-Faktor: 3,3
  23. Westphal S, Luley C. Flavanol ameliorates lipemia-induced endothelial dysfunction. Heart Vessels. 2011;26:511-5. Impact-Faktor: 1,7
  24. Luley C, Blaik A, Aronica S, Dierkes J, Kropf S, Westphal S. Evaluation of Three New Strategies to Fight Obesity in Families. J Nutr Metab. 2010;2010. pii: 751905. doi: 10.1155/2010/751905. Impact-Faktor: 2,03
  25. Luley C, Blaik A, Reschke K, Klose S, Westphal S. Weight loss in obese patients with type 2 diabetes: Effects of telemonitoring plus a diet combination - The Active Body Control (ABC) Program. Diabetes Res Clin Pract. 2011;91:286-92. Impact-Faktor: 2,1
  26. Steiner J, Bernstein HG, Schiltz K, Haase T, Meyer-Lotz G, Dobrowolny H, Müller UJ, Martins-de-Souza D, Borucki K, Schroeter ML, Isermann B, Bogerts B, Westphal S. Decrease of serum S100B during an oral glucose tolerance test correlates inversely with the insulin response. Psychoneuroendocrinology. 2014;39:33-8. Impact-Faktor: 4,7
  27. Luley C, Blaik A, Götz A, Kicherer F, Kropf S, Isermann B, Stumm G, Westphal S. Weight loss by telemonitoring of nutrition and physical activity in patients with metabolic syndrome for 1 year. J Am Coll Nutr. 2014;33:363-74.